• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Kumar Krishna

    6/23/23 4:40:39 PM ET
    $AKU
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Kumar Krishna

    (Last) (First) (Middle)
    C/O AKUMIN INC.
    8300 W. SUNRISE BOULEVARD

    (Street)
    PLANTATION FL 33322

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/16/2023
    3. Issuer Name and Ticker or Trading Symbol
    AKUMIN INC. [ AKU ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See remarks
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    President and Chief Operating Officer Exhibit List - Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/Thomas P. Conaghan as attorney-in-fact 06/23/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AKU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKU

    DatePrice TargetRatingAnalyst
    11/14/2022$3.50 → $3.00Buy → Speculative Buy
    Canaccord Genuity
    More analyst ratings

    $AKU
    Financials

    Live finance-specific insights

    See more
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Second Quarter 2023 Results, Revised FY23 Financial Outlook and Establishment of Special Committee

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Akumin delivered second quarter same-store volume performance on a consolidated basis as follows:+3.1% for MRI+16.5% for PET/CT+3.4% for Oncology Patient StartsThe Company reported revenue totaling $184.8 million for the second quarter, a $7.3 million or 4% decrease over the second quarter of last year.

      8/9/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin to Host Second Quarter 2023 Financial Results Call on August 10, 2023

      PLANTATION, Fla., Aug. 8, 2023 /PRNewswire/ - Akumin Inc. (TSX:AKU) ("Akumin" or the "Company") will host a conference call at 8:30 a.m. Eastern Time, Thursday, August 10, 2023, to discuss its second quarter 2023 financial results.  The financial results are expected to be available on Wednesday, August 9, 2023. To access the conference call, participants may join by using an appropriate dial-in number available through https://akum.in/Q2-2023-Results-Dial-In-Numbers or via webcast at https://akum.in/Q2-2023-Results-Webcast. A related presentation will be available from Akumin's website (www.akumin.com). Participants are asked to connect at least 10 minutes prior to the beginning of the call

      8/8/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Leadership Updates

    Live Leadership Updates

    See more
    • AKUMIN ANNOUNCES LEADERSHIP TRANSITION

      PLANTATION, Fla., Dec. 29, 2023 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and

      12/29/23 7:52:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Change of Auditor

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) announced today that it has changed its auditor from Ernst & Young LLP ("EY") to Deloitte & Touche LLP ("Deloitte"). Effective as of August 9, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of the Company dismissed EY as the Company's independent registered public accounting firm. EY audited the Company's financial statements for each of the past two fiscal years ended December 31, 2022 and 2021, and EY's reports did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or

      8/9/23 5:31:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin appoints President and Chief Operating Officer

      PLANTATION, Fla., June 12, 2023 /CNW/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) today announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joini

      6/12/23 6:59:57 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akumin Announces Changes to Leadership Team

      Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer Chandra Westergaard Named General Counsel PLANTATION, Fla., Feb. 8, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") announced today that Krishna Kumar, who has served as President and Chief Operating Officer at the Company, has been appointed Chief Executive Officer, effective immediately. He succeeds Riadh Zine, Akumin's Founder, who is stepping down as Chairman and Chief Executive Officer. Akumin also announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. "On behalf of Akumin, I would like to thank Riadh for his dedica

      2/8/24 5:00:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

      Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S. PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete. "We are pleased to have concluded this process and are excited to enter our next chapt

      2/6/24 6:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:37:41 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Akumin Inc.

      SC 13G - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:31:27 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/7/24 10:43:55 AM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Akumin from Buy to Speculative Buy and set a new price target of $3.00 from $3.50 previously

      11/14/22 8:59:34 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Foursixthree Capital Lp claimed ownership of 10,556,851 shares (SEC Form 3)

      3 - AKUMIN INC. (0001776197) (Issuer)

      2/5/24 4:50:02 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Bienias Ronald J.

      3 - AKUMIN INC. (0001776197) (Issuer)

      10/26/23 10:40:46 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Kumar Krishna

      4 - AKUMIN INC. (0001776197) (Issuer)

      7/18/23 1:31:57 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    SEC Filings

    See more
    • SEC Form EFFECT filed by Akumin Inc.

      EFFECT - AKUMIN INC. (0001776197) (Filer)

      2/13/24 12:15:09 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by Akumin Inc.

      15-12G - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:11:57 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Akumin Inc.

      S-8 POS - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:09:57 AM ET
      $AKU
      Medical Specialities
      Health Care